Dr. Neelanjan Bose has just been awarded the prestigious Larry L. Hillblom Fellowship. This is a three year fellowship allowing Dr. Bose to proceed with and advance his research on the role of advanced glycation endproducts in aging and neurodegeneration.
As part of the Cornell/Rockefeller/Sloan-Kettering Tri-Institutional Training Program in Chemical Biology (TPCB), his graduate training has been in a thoroughly multidisciplinary environment. His primary research interest was to study small molecule signaling, and their role in mediating diseases pathways. During his graduate studies, he developed and validated an innovative workflow utilizing a combination of analytical chemistry (LC-MS/MS and 2D NMR) and molecular biology for the identification of trace metabolites and novel chemical markers from complex biological matrices. Ultimately, his research led to the successful discovery of several dozen new natural products with potent biological activities and unusual structural features such as xylopyranose-based nucleosides.
During his PhD research, he primarily focused on method development, with the primary goal of establishing a cutting-edge analytical workflow for small molecule studies. Even though his research was quite successful, he always felt a tangible void in terms of direct applicability of his results towards clinical care. He was thus determined to bridge this gap through his postdoctoral research. Thus, he joined Prof. Kapahi’s group at the Buck Institute for Research on Aging as he saw a tremendous potential for both intellectual and scientific advancement, as well as the ability to collaborate with clinicians. His collaboration with these clinicians ultimately led him to Drs. Marshall Stoller and Tom Chi of the Urology Department at UCSF, a clinical research group he eventually joined. Dr. Kapahi, though, continues to mentor and provide guidance as part of the collaborative research group.
The goal of his proposed research is to study the role of a class of reactive metabolites, called α- dicarbonyl compounds (α-DCs) and their derivatives, advanced glycation endproducts (AGEs). α-DCs and AGEs are major pathogenic mediators of various aging-associated pathologies, such as diabetic complications and neurodegenerative disorders. With this project, he hopes to delineate the biochemical cross-talk between AGE-stress, diabetes, and neurodegenerative diseases, such as Parkinson’s disease. He is already on the path to developing novel therapeutic routes for these debilitating disorders.
This Larry L. Hillblom Foundation fellowship will provide him with an excellent opportunity to fulfill his passion of bringing basic research to the patients. He has decided to focus his training in the field of analytical chemistry to solve problems directly related to patient care.